Displaying Results 46 - 51 of 51
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.
Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.
Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for “over-treatment.”
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
